FNIII 14 Peptide

<strong>FNIII 14 Peptide </strong>_x000D_ <strong>Catalog number:</strong> B2014698_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 2 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 2357 g/mol_x000D_ <strong>Supplied as:</strong> Solid_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> TEATITGLEPGTEYTITYVIAL, Thr-Glu-Ala-Thr-Ile-Thr-Gly-Leu-Glu-Pro-Gly-Thr-Glu-Tyr-Thr-Ile-Thr-Tyr-Val-Ile-Ala-Leu, threonyl-α-glutamyl-alanyl-threonyl-isoleucyl-threonyl-glycyl-leucyl-α-glutamyl-prolyl-glycyl-threonyl-α-glutamyl-tyrosyl-threonyl-isoleucyl-threonyl-tyrosyl-valyl-isoleucyl-alanyl-leucine_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Julier Z, Martino MM, de Titta A, Jeanbart L, Hubbell JA. The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine Sci Rep. 2015 Feb 24;5:8569._x000D_ 2: Moulisová V, Gonzalez-García C, Cantini M, Rodrigo-Navarro A, Weaver J, Costell M, Sabater I Serra R, Dalby MJ, García AJ, Salmerón-Sánchez M. Engineered microenvironments for synergistic VEGF - Integrin signalling during vascularization Biomaterials. 2017 May;126:61-74._x000D_ 3: Tarnovskaya S, Kiselev A, Kostareva A, Frishman D. Structural consequences of mutations associated with idiopathic restrictive cardiomyopathy Amino Acids. 2017 Nov;49(11):1815-1829._x000D_ 4: De Laporte L, Rice JJ, Tortelli F, Hubbell JA. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain PLoS One. 2013 Apr 18;8(4):e62076._x000D_ 5: Russell TM, Delorey MJ, Johnson BJ. Borrelia burgdorferi BbHtrA degrades host ECM proteins and stimulates release of inflammatory cytokines in vitro Mol Microbiol. 2013 Oct;90(2):241-51._x000D_ 6: Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, Patel Y, Suda Y, Humphries MJ, Sobel M. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism Circ Res. 2006 Oct 13;99(8):853-60._x000D_ 7: Ikuta T, Sogawa N, Ariga H, Ikemura T, Matsumoto K. Structural analysis of mouse tenascin-X: evolutionary aspects of reduplication of FNIII repeats in the tenascin gene family Gene. 1998 Sep 14;217(1-2):1-13._x000D_ 8: Johnson KJ, Sage H, Briscoe G, Erickson HP. The compact conformation of fibronectin is determined by intramolecular ionic interactions J Biol Chem. 1999 May 28;274(22):15473-9._x000D_ 9: Yang F, West AP Jr, Allendorph GP, Choe S, Bjorkman PJ. Neogenin interacts with hemojuvelin through its two membrane-proximal fibronectin type III domains Biochemistry. 2008 Apr 8;47(14):4237-45._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/19139090">10: Alvino CL, McNeil KA, Ong SC, Delaine C, Booker GW, Wallace JC, Whittaker J, Forbes BE. A novel approach to identify two distinct receptor binding surfaces of insulin-like growth factor II J Biol Chem. 2009 Mar 20;284(12):7656-64. </a>_x000D_ _x000D_ <strong>Products Related to FNIII 14 Peptide can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>